About ArpIda
ArpIda is a company based in Reinach (Switzerland) founded in 1997 was acquired by Evolva in September 2009.. ArpIda has raised $90.4 million across 3 funding rounds from investors including Evolva, Carlsberg Group and O-Bank. ArpIda operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Reinach, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ArpIda
ArpIda has successfully raised a total of $90.4M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $26.4 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $26.4M
-
First Round
First Round
(08 Nov 2000)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2004 | Amount | Series C - ArpIda | Valuation | Carlsberg Group , LD Fonde | |
| May, 2004 | Amount | Series C - ArpIda | Valuation |
investors |
|
| Nov, 2000 | Amount | Series A - ArpIda | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ArpIda
ArpIda has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Evolva, Carlsberg Group and O-Bank. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ArpIda
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ArpIda
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arpida Comparisons
Competitors of ArpIda
ArpIda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about ArpIda
When was ArpIda founded?
ArpIda was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Where is ArpIda located?
ArpIda is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
Is ArpIda a funded company?
ArpIda is a funded company, having raised a total of $90.4M across 3 funding rounds to date. The company's 1st funding round was a Series A of $23M, raised on Nov 08, 2000.
What does ArpIda do?
ArpIda was founded in 1997 and is based in Reinach, Switzerland. Operations center on the pharmaceutical sector, with emphasis placed on antibiotics to address microbial resistance. The lead product candidate, intravenous iclaprim, is designed for hospital-treated severe infections, such as those from methicillin-resistant Staphylococcus aureus (MRSA). Development efforts target unmet needs in infectious disease management.
Who are the top competitors of ArpIda?
ArpIda's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are ArpIda's investors?
ArpIda has 8 investors. Key investors include Evolva, Carlsberg Group, O-Bank, CDIB Capital Group, and LD Fonde.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.